Drug combination for relapsed or resistant solid tumors in children
Part of Cancer clinical trials.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or haven't responded to standard treatment. The goal is to see if this drug mix can shrink or control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 18 years old
- Your tumor is a solid tumor (like neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, or osteosarcoma) that has come back or is resistant to treatment
- You have at least one tumor that can be measured on a CT or MRI scan
- You are physically able to carry out daily activities (ECOG score 0, 1, or 2)
- Your blood counts and liver/kidney function are within acceptable ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs (irinotecan, temozolomide, and vincristine) in children and teens whose solid tumors have come back or stopped responding to standard treatment. The goal is to see if this combination can help shrink or control the tumors.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
Hear when a new Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.